ING Groep NV Increases Stake in Kenvue Inc. (NYSE:KVUE)

ING Groep NV increased its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 23.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,576,616 shares of the company's stock after purchasing an additional 681,954 shares during the quarter. ING Groep NV owned approximately 0.19% of Kenvue worth $82,727,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Riverview Trust Co bought a new stake in shares of Kenvue in the third quarter worth $30,000. Ashton Thomas Securities LLC bought a new stake in Kenvue during the third quarter valued at $35,000. Studio Investment Management LLC boosted its position in Kenvue by 52.1% during the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company's stock valued at $45,000 after acquiring an additional 845 shares during the last quarter. Deseret Mutual Benefit Administrators boosted its position in Kenvue by 49.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company's stock valued at $45,000 after acquiring an additional 651 shares during the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in Kenvue during the second quarter valued at $61,000. Institutional investors own 97.64% of the company's stock.

Kenvue Trading Up 2.0 %

Kenvue stock traded up $0.47 during mid-day trading on Thursday, hitting $23.61. The company's stock had a trading volume of 14,014,756 shares, compared to its average volume of 18,062,609. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The stock has a market cap of $45.27 billion, a price-to-earnings ratio of 42.62, a price-to-earnings-growth ratio of 2.15 and a beta of 1.36. The business has a 50 day moving average price of $22.73 and a 200-day moving average price of $20.63. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $23.95.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. During the same period in the previous year, the firm posted $0.31 earnings per share. The firm's revenue for the quarter was down .4% on a year-over-year basis. As a group, analysts forecast that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.47%. The ex-dividend date is Wednesday, November 13th. Kenvue's payout ratio is 149.09%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on KVUE. UBS Group upped their price target on shares of Kenvue from $20.00 to $22.00 and gave the company a "neutral" rating in a research report on Wednesday, August 7th. Piper Sandler increased their price objective on shares of Kenvue from $20.00 to $21.00 and gave the stock a "neutral" rating in a research report on Monday, September 23rd. Royal Bank of Canada cut shares of Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 price objective on the stock. in a research report on Tuesday, September 24th. Jefferies Financial Group assumed coverage on shares of Kenvue in a research report on Tuesday, September 24th. They set a "buy" rating and a $27.00 price objective on the stock. Finally, Bank of America increased their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock a "buy" rating in a research report on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Kenvue currently has an average rating of "Hold" and an average target price of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.